ClinicalTrials.gg
CompletedNCT05932485Updated Dec 22, 2025

Effect of Stellate Ganglion Block on New Atrial Fibrillation After Coronary Artery Bypass Grafting

An interventional study of Stellate nerve block in Stellate Ganglion Block, sponsored by Yangzhou University. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by Yangzhou University · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Post-operative new-onset atrial fibrillation (POAF) is one of the most common arrhythmias in adults after direct intracardiac surgery with extracorporeal circulation. The incidence of POAF in coronary artery bypass grafting (CABG) is approximately 30%. POAF can lead to an increased risk of complications such as stroke, heart failure, and acute kidney injury, which not only prolongs the patient's hospital stay, but also increases hospital costs and mortality. operation, extracorporeal circulation, and the patient's underlying conditions (such as age, gender, hypertension, and diabetes), which cause sympathetic activation, inflammatory response, and myocardial ischemia in the organism. The stellate ganglion block (SGB) regulates the sympathetic tone of the innervated nerves and thus the autonomic function of the body. SGB can effectively regulate the sympathetic-parasympathetic imbalance. Also, SGB may exert some anti-inflammatory effects. In this study, ultrasound-guided SGB was used in CABG patients to investigate its effect on the occurrence of POAF.

02

Conditions studied

  • Stellate Ganglion Block

Browse trials for

03

In context

Ganglion Cysts

42 studies on the registry are indexed under Ganglion Cysts; 7 are open to participants now.

This study's enrollment of 108 is above the median of 62 across 31 interventional studies indexed under Ganglion Cysts.

Browse Ganglion Cysts studies →

Lead sponsor

Yangzhou University is the lead sponsor of 41 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing first-time and elective coronary artery bypass grafting;
  • II-IV;
  • The preoperative showed sinus heart rate.

Exclusion criteria

Exclusion Criteria:

  • The patient refused to participate in this study;
  • Surgical procedures include any other type of heart surgery in addition to CABG;
  • Allergic to known general anesthesia drugs;
  • Patients with a history of neck surgery or abnormal neck anatomy;
  • Patients with to SGB.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
108 participants (actual)

Study arms

  • Experimental
    Left stellate ganglion block

    Left stellate ganglion block under ultrasound guidance was administered with 0.375% Ropivacaine hydrochloride 5 ml

    Procedure: Stellate nerve block

  • No intervention
    Control

    do nothing

Interventions

  • ProcedureStellate nerve block

    Before the operation, the left stellate ganglion block was performed, and 0.375% ropivacaine 5ml was injected into the stellate ganglion.

06

What researchers measure

Primary outcomes

  1. The occurrence of new atrial fibrillation was detected by ECG monitoring

    ECG monitor shows atrial fibrillation. To be specific: 1)Irregular R-R interval (when atrioventricular conduction is present), 2) P wave disappearance, 3) irregular atrial activity.

    Time frame: Within 5 days after surgery

Secondary outcomes

  1. AF burden

    The percentage of the time during which atrial fibrillation occurs in the overall recorded time.

    Time frame: within 5 days after surgery

  2. Duration of the first episode of POAF

    The duration from the onset to the resolution of the first atrial fibrillation after surgery.

    Time frame: within 5 days after surgery

  3. Need for Antiarrhythmic treatments

    Record the types of medications used and whether electrical cardioversion has been used.

    Time frame: within 5 days after the operation

  4. the concentration of interleukin-6

    Interleukin-6 (IL-6) is an important cytokine that plays a key role in immune responses, inflammation, and tumor development.

    Time frame: end of surgery, 24 hour postoperatively, 72hour postoperatively, 5 day postoperatively

  5. the concentration of CRP

    C-reactive protein (CRP) is a protein produced by the liver that is mainly used to indicate the presence of inflammation in the body.

    Time frame: end of surgery,24 hour postoperatively ,72 hour postoperatively ,5 day postoperatively

  6. Changes of intraoperative Left ventricular diastolic function

    Left ventricular diastolic function were measured by transesophageal echocardiography (TEE)

    Time frame: T1 (after sternotomy and before CPB) and T2 (30 minute after CPB cessation).

  7. the concentration of Hs-cTnT

    hs-cTnT is an important biomarker used for detecting cardiac injury.

    Time frame: end of surgery, 24hour postoperatively, 72hour postoperatively

  8. the concentration of CK-MB

    CK-MB is an enzyme primarily found in cardiac muscle cells. Its concentration is commonly used to assess cardiac damage, especially in the case of myocardial infarction

    Time frame: end of surgery, 24hour postoperatively, 72hour postoperatively

  9. postoperative adverse reactions

    Record the occurrence of adverse reactions postoperative

    Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months

07

Study locations

1 site
  • the Affiliated Hospital of Yangzhou University, Yangzhou University
    Yangzhou, Jiangsu, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jun 2024, 12 months.

Of 16 interventional studies with no phase under Ganglion Cysts, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 26. This study's 12 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 10, 2023
First posted
Jul 6, 2023
StartActual
Jun 1, 2023
Primary completionActual
Jun 1, 2024
CompletionActual
Jun 1, 2024
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05932485
Lead sponsor
Yangzhou University
Responsible party
Zhuan Zhang (MD, the Deputy Director of Anesthesiology, the Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou University) — Principal investigator
First posted
Jul 6, 2023
Start date
Jun 1, 2023
Primary completion
Jun 1, 2024
Completion
Jun 1, 2024
Last update
Dec 22, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion